US · HRMY
Harmony Biosciences Holdings, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Plymouth Meeting, PA 19462
- Website
- harmonybiosciences.com
Price · as of 2025-12-31
$31.83
Market cap 1.64B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $72.71 | +128.43% |
| Intrinsic Value(DCF) | $202.25 | +535.41% |
| Graham-Dodd Method(GD) | $28.94 | -9.09% |
| Graham Formula(GF) | $79.47 | +149.66% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $30.52 | $410.86 | $1,616,390.22 | $0.00 | $0.00 |
| 2021 | $43.86 | $906.37 | $8.34 | $6.25 | $57.35 |
| 2022 | $41.26 | $64.28 | $6,558.59 | $22.14 | $152.24 |
| 2023 | $31.09 | $62.87 | $1,084.54 | $18.69 | $86.01 |
| 2024 | $33.67 | $76.42 | $401.03 | $24.38 | $76.57 |
| 2025 | $28.90 | $72.71 | $391.72 | $28.94 | $79.47 |
AI valuation
Our deep-learning model estimates Harmony Biosciences Holdings, Inc.'s (HRMY) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $72.71
- Current price
- $31.83
- AI upside
- +128.43%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$202.25
+535.41% upside
Graham-Dodd
$28.94
-9.09% upside
Graham Formula
$79.47
+149.66% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| HRMY | Harmony Biosciences Holdi… | $31.83 | 1.64B | +128% | +535% | -9% | +150% | — | 1.91 | 1.91 | 4.41 | — | 2.13 | 77.16% | 24.00% | 18.27% | 0.00% | 43.46% | 0.00% | 0.28 | 14.23 | 3.60 | 3.46 | -2.01 | 797.00% | 2151.00% | 5909.00% | 20.94% | 1.38 | 98.30% | 0.00% | — | 14.52% | 5.40 | 3.24 | 1.30 | 4.50 |
| ABCL | AbCellera Biologics Inc. | $3.61 | 1.08B | +1,038% | -58% | -83% | — | -7.79 | 1.18 | 15.19 | -5.71 | — | 1.30 | 100.00% | -288.98% | -194.88% | -14.47% | -29.60% | -10.78% | 0.29 | — | 11.32 | 9.21 | -0.98 | -1091.00% | 16056.00% | -689.00% | -15.25% | -2.04 | -28.78% | 0.00% | 0.00% | 0.00% | -4.09 | -5.10 | 11.82 | 2.19 |
| AUPH | Aurinia Pharmaceuticals I… | $14.17 | 1.87B | +206% | +451% | +6% | +317% | 6.65 | 3.28 | 6.75 | 12.42 | 0.13 | 3.31 | 88.46% | 37.06% | 101.47% | 59.91% | 58.85% | 44.11% | 0.13 | 24.23 | 5.25 | 4.69 | -0.04 | 516718.00% | 2038.00% | 20699.00% | 7.09% | 1.45 | 75.96% | 0.00% | 0.00% | 5.21% | 15.12 | 11.71 | 5.60 | 6.99 |
| BHVN | Biohaven Ltd. | $11.52 | 1.22B | — | — | — | — | -3.22 | 6.43 | — | -2.59 | -5.20 | 6.75 | 0.00% | — | — | -198.83% | -3466.81% | -150.03% | 0.09 | — | 3.49 | 3.17 | 0.07 | 6195.00% | — | 7519.00% | -21.53% | -3.78 | -2297.22% | 0.00% | 0.00% | 0.00% | -2.57 | -3.88 | — | 1.47 |
| CLDX | Celldex Therapeutics, Inc… | $30.09 | 2B | +2% | -54% | — | +767% | -7.71 | 3.78 | 1330.00 | -5.79 | -13.03 | 3.99 | 100.00% | -19160.00% | -17253.33% | -40.62% | -1576.31% | -37.63% | 0.00 | — | 10.49 | 10.21 | 0.10 | 5918.00% | -7863.00% | 3379.00% | -10.71% | -4.14 | -1171.86% | 0.00% | 0.00% | 0.10% | -5.15 | -6.92 | 985.84 | 16.46 |
| IMCR | Immunocore Holdings plc | $32.30 | 1.64B | +113% | -48% | -85% | — | -46.31 | 4.32 | 5.53 | 2128.75 | — | 4.32 | 97.91% | -11.34% | -8.88% | -9.58% | 14.46% | -3.42% | 0.11 | -2.77 | 4.04 | 3.80 | -1095.49 | -4804.00% | 2010.00% | -15893.00% | -0.75% | -0.03 | 5.28% | 0.00% | 0.00% | 24.39% | -24.43 | -66.96 | 2.77 | 1.37 |
| JANX | Janux Therapeutics, Inc. | $13.61 | 818.61M | +171% | -7% | -80% | — | — | 0.87 | 83.16 | 0.99 | — | 0.87 | 79.71% | -1576.67% | -1576.67% | 0.00% | -954.78% | 0.00% | 0.02 | — | 39.04 | 38.67 | 0.27 | 4297.00% | -555.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | — | 0.00% | 0.72 | — | -11.28 | 11.29 |
| MNKD | MannKind Corporation | $3.28 | 1.01B | +882% | +28% | — | -83% | 158.21 | -18.18 | 2.66 | 29.19 | — | -7.50 | 82.47% | 11.12% | 1.68% | -9.03% | -19.22% | 0.99% | -0.92 | 2.81 | 1.70 | 1.23 | -1.01 | -7942.00% | 2223.00% | -5829.00% | 1.48% | 0.11 | -6.78% | 0.00% | 0.00% | 3.16% | 20.70 | 58.68 | 2.30 | -4.20 |
| NUVB | Nuvation Bio Inc. | $5.91 | 2.02B | — | — | — | — | -0.96 | 1.17 | 68.96 | -0.09 | -0.19 | 1.18 | 10.10% | -7527.33% | -7213.76% | -106.27% | 3695.49% | -97.74% | 0.02 | -1737.91 | 9.04 | 8.91 | 0.05 | 50286.00% | — | 9183.00% | -24.05% | -2.24 | 814.24% | 0.00% | 0.00% | 0.00% | -0.08 | -0.38 | 6.24 | -0.68 |
| SION | Sionna Therapeutics, Inc. | $36.54 | 1.63B | — | — | — | — | -11.64 | -4.39 | — | -8.30 | -37.90 | -4.39 | 0.00% | — | — | 44.29% | 31.75% | -51.90% | -0.06 | — | 14.49 | 14.16 | 0.40 | 3071.00% | — | 1785.00% | -7.36% | -5.07 | 23.77% | 0.00% | 0.00% | 0.00% | -8.22 | -10.98 | — | -0.48 |
| VERA | Vera Therapeutics, Inc. | $40.79 | 2.86B | — | — | — | — | -8.67 | 4.29 | — | -6.55 | -12.48 | 4.29 | 0.00% | — | — | -50.71% | 1508.68% | -43.10% | 0.13 | — | 13.64 | 13.37 | 0.93 | 6945.00% | — | 7820.00% | -9.31% | -4.51 | 1156.04% | 0.00% | 0.00% | 9.22% | -6.21 | -8.10 | — | 10.20 |
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
- CEO
- Jeffrey Dayno
- Employees
- 268
- Beta
- 0.84
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($202.25 ÷ $31.83) − 1 = +535.41% (DCF, example).